Application Progress of Immune Checkpoint Inhibitors
in Oncogene-driven Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2021.101.04
- Author:
Tongmei ZHANG
1
;
Baolan LI
1
Author Information
1. Beijing Chest Hospital, Capital Medical University, Beijing Tuberculosis and Thoracic Tumor Research Institute,
Beijing 101149, China.
- Publication Type:Journal Article
- Keywords:
Immune Checkpoint Inhibitors;
Lung neoplasms;
Oncogene;
Predictor
- From:
Chinese Journal of Lung Cancer
2021;24(3):188-195
- CountryChina
- Language:Chinese
-
Abstract:
With the development of precise medicine, targeted therapy has greatly improved the survival and prognosis of patients in advanced non-small cell lung cancer (NSCLC) with oncogenic drivers. However, no matter which kinds of targeted therapy are inevitable to develop therapeutic resistance, treatment options upon exhaustion of targeted therapies are limited. Immune checkpoint inhibitors (ICIs) can bring long-term survival to some patients with advanced NSCLC because of its unique long tailing effect. More and more studies have shown that ICIs can also benefit NSCLC patients with oncogenic drivers. However, the timing of ICIs intervention, the therapeutic regimen and the predictive biomarkers are actually debated, underscoring the need to explore the potential interest of ICIs in these populations.
.
